Skip to main content

Table 1 Clinical data

From: Modulation of deoxycytidine kinase (dCK) and glycogen synthase kinase (GSK-3β) by anti-CD20 (rituximab) and 2-chlorodeoxyadenosine (2-CdA) in human lymphoid malignancies

Patient demographics  
  Total number of patients 13
  Male: Female 7:6
  Median Age at Diagnosis in years (range) 48 (39–71)
  Median Age at R-2CdA treatment (range) 59 (40–76)
Histology  
  Chronic lymphocytic leukemia/small 9
  Lymphocytic lymphoma (CLL/SLL)  
  Waldenstrom’s Macroglobulinemia (WM) 3
  Follicular lymphoma Grade I/II 1
Stage  
  Rai Stage IV 6/8
  Ann Arbor (AA) Stage IV 4/4
  Not determined 1
Prior therapy  
  Previously treated 12
  Median number of prior regimens (range) 3 (2–7)
Response  
  Total response rate (RR) (number/percent) 10/13 (77%)
  Complete response (CR) 7/13 (54%)
  Partial response (PR) 3/13 (23%)
  Progressive disease (PD) 3/13 (23%)
  Median duration of response (range) 34 months (8-118+)
Common toxicity Grade
Total % 1 2 3 4
  Anemia 8 (62%) 6 1 1  
  Thrombocytopenia 8 (62%) 5 1 2  
  Neutropenia 7 (54%) 2 3 2  
  Fatigue 7 (54%) 2 3 2  
  Weight loss 5 (38%) 3 2